Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + bevacizumab vs capecitabine + bevacizumab in first-line HER2-negative metastatic breast cancer
2007-005828-32Phase 3Completed
- Sponsor
- Central European Cooperative Oncology Group
- Start
- Mar 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing paclitaxel + bevacizumab with capecitabine + bevacizumab (2 arms). Primary endpoint: overall survival. Started Mar 2008; status: completed.
02
Drugs
bevacizumabpaclitaxelcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-005828-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005828-32.